Current status and future perspectives of dendritic cell-based cancer immunotherapy.
about
Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancerp38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.CCL21 Cancer Immunotherapy.Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.DNA is an efficient booster of dendritic cell-based vaccineInterleukin-10 reorganizes the cytoskeleton of mature dendritic cells leading to their impaired biophysical properties and motilitiesMaterials that harness and modulate the immune system.Investigations of the functional states of dendritic cells under different conditioned microenvironments by Fourier transformed infrared spectroscopy.Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematologyDendritic Cell-Derived Exosomes may be a Tool for Cancer Immunotherapy by Converting Tumor Cells into Immunogenic Targets.Brain Tumor Immunotherapy: What have We Learned so Far?Dendritic cell-based immunotherapy: a basic review and recent advances.Optimizing the process of nucleofection for professional antigen presenting cells.mRNA-based vaccines synergize with radiation therapy to eradicate established tumors.Potential applications of nanoparticles in cancer immunotherapy.Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma.Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer.
P2860
Q28392626-DA25A79D-711A-4C27-954C-B87FC9036336Q30422500-43553C3A-B494-472E-A572-61EE2CCB24D3Q33820300-7A919CE8-75E5-4ED9-81A5-DABCB76603BFQ34467270-C4EA35CA-52B6-4459-BC77-9B79C9D07565Q36256389-939DE1ED-FC10-40C3-8BC8-CC454BF04E1EQ36289748-7CBB0FEB-5E29-4982-BFF4-B5054DA9CD73Q36690859-FD288E28-8000-4B21-8733-4DFB880A1AF8Q37501316-FCEF0C5B-CF08-4E39-AAFB-0031EBBFF9E7Q37676065-208DA78E-DB59-4787-8E7D-14B05D8657E3Q38237590-088E6E5A-3BFC-4242-86D9-8A2E033DD441Q38342134-79C01120-5DCD-4B31-80AA-BDFD5BBB6D9EQ38542113-CEDF0B98-9710-436A-B2B4-31838BD7CB70Q38665350-5B4B3D36-1DEA-4737-B081-6A8E63D76146Q38832705-660E0E4C-0267-4983-9071-9A7B7AD9469CQ38965661-B9231533-1B75-4FC9-8552-2BF8A31FF30FQ39015434-7083CDCD-7247-4258-9B7A-846E3F987C4FQ41062063-4C20EA87-3187-4BEC-8A0C-8CDDA5E287FBQ50544084-42EC3376-72EC-441F-8F81-840B01A2BE0C
P2860
Current status and future perspectives of dendritic cell-based cancer immunotherapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Current status and future perspectives of dendritic cell-based cancer immunotherapy.
@en
type
label
Current status and future perspectives of dendritic cell-based cancer immunotherapy.
@en
prefLabel
Current status and future perspectives of dendritic cell-based cancer immunotherapy.
@en
P2860
P356
P1476
Current status and future perspectives of dendritic cell-based cancer immunotherapy
@en
P2093
P2860
P304
P356
10.1111/SJI.12060
P50
P577
2013-08-01T00:00:00Z